Influence of Molecular Size on the Retention of Polymeric Nanocarrier Diagnostic Agents in Breast Ducts

详细信息    查看全文

• 作者：Yashveer Singh (1)
  Dayuan Gao (1)
  Zichao Gu (1)
  Shike Li (1)
  Kristia A. Rivera (1)
  Stanley Stein (1)
  Susan Love (2)
  Patrick J. Sinko (1) sinko@rci.rutgers.edu
• 关键词：KEY WORDS ductal carcinoma in situ (DCIS) – ; ductal retention – ; intraductal drug delivery – ; non ; invasive imaging – ; PEG nanocarriers
• 刊名：Pharmaceutical Research
• 出版年：2012
• 出版时间：September 2012
• 年：2012
• 卷：29
• 期：9
• 页码：2377-2388
• 全文大小：526.3 KB
• 参考文献：1. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350(14):1430–41.
  2. Peterson JL, Vallow LA, Hines SL, Buskirk SJ. Ductal carcinoma in situ of the breast. Oncol Rev. 2009;3:237–46.
  3. Silverstein MJ. Ductal carcinoma in situ of the breast. Annu Rev Med. 2000;51:17–32.
  4. Love SM, Barsky SH. Anatomy of the nipple and breast ducts revisited. Cancer. 2004;101(9):1947–57.
  5. Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1-2 breast carcinomas. Implications for clinical trials of breast-conserving surgery. Cancer. 1985;56(5):979–90.
  6. American Cancer Society. Cancer facts and figures 2011. Available from: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2011
  7. Virnig BA, Shamliyan T, Tuttle TM, Kane RL, Wilt WJ. Diagnosis and management of ductal carcinoma in situ (DCIS): Evidence report/Technology assessment, No. 185. Rockville, MD, 2009
  8. Flanagan M, Love S, Hwang ES. Status of intraductal therapy for ductal carcinoma in situ. Curr Breast Cancer Rep. 2010;2(2):75–82.
  9. King BL, Love SM. The intraductal approach to the breast: raison d’etre. Breast Cancer Res. 2006;8(2):206.
  10. Love SM, Barsky SH. Breast-duct endoscopy to study stages of cancerous breast disease. Lancet. 1996;348(9033):997–9.
  11. Jacobs VR, Paepke S, Schaaf H, Weber BC, Kiechle-Bahat M. Autofluorescence ductoscopy: a new imaging technique for intraductal breast endoscopy. Clin Breast Cancer. 2007;7(8):619–23.
  12. Goulet RJ, Badve S, Brannon-Peppas L, Rouch D, Huntley C, Storniolo AM. Pilot trial assessing the feasibility of intra-ductal delivery of epirubicin (epi)-containing nanoparticles (np) via InDuct breast microcatheter (IDBM). J Clin Oncol. 2004;22(14S):828.
  13. McFarlin DR, Gould MN. Rat mammary carcinogenesis induced by in situ expression of constitutive Raf kinase activity is prevented by tethering Raf to the plasma membrane. Carcinogenesis. 2003;24(6):1149–53.
  14. Okugawa H, Yamamoto D, Uemura Y, Sakaida N, Tanano A, Tanaka K, Kamiyama Y. Effect of perductal paclitaxel exposure on the development of MNU-induced mammary carcinoma in female S-D rats. Breast Cancer Res Treat. 2005;91(1):29–34.
  15. Murata S, Kominsky SL, Vali M, Zhang Z, Garrett-Mayer E, Korz D, Huso D, Baker SD, Barber J, Jaffee E, Reilly RT, Sukumar S. Ductal access for prevention and therapy of mammary tumors. Cancer Res. 2006;66(2):638–45.
  16. Stearns V, Mori T, Jacobs LK, Khouri NF, Gabrielson E, Yoshida T, Kominsky SL, Huso DL, Jeter S, Powers P, Tarpinian K, Brown RJ, Lange JR, Rudek MA, Zhang Z, Tsangaris TN, Sukumar S. Preclinical and clinical evaluation of intraductally administered agents in early breast cancer. Sci Transl Med. 2011;3(106):106ra108.
  17. Mahoney ME, Mills DJ, Love S. Intraductal therapy of DCIS with liposomal doxorubicin: a preoperative trial in rural California. BMC Proc. 2009;3:S31.
  18. Chen Z, Mei D, Dai Y-Y, Tang Z-Q. Plasma concentration of doxorubicin after intraductal administration of doxorubicin long-circulating liposome in patients with breast cancer. Chinese Pharm J. 2010;45(20):1585–8.
  19. Love SM, Zhang B, Zhang W, Zhang B, Yang H, Rao J. Local drug delivery to the breast: a phase I study of breast cytotoxic agent administration prior to mastectomy. BMC Proc. 2009;3:S29.
  20. Singh Y, Gao D, Gu Z, Li S, Stein S, Sinko PJ. Noninvasive detection of passively targeted poly(ethylene glycol) nanocarriers in tumors. Mol Pharm. 2012;9:144–55.
  21. Chao P, Deshmukh M, Kutscher HL, Gao D, Rajan SS, Hu P, Laskin DL, Stein S, Sinko PJ. Pulmonary targeting microparticulate camptothecin delivery system: anticancer evaluation in a rat orthotopic lung cancer model. Anticancer Drugs. 2010;21(1):65–76.
  22. Kutscher HL, Chao P, Deshmukh M, Sundara Rajan S, Singh Y, Hu P, Joseph LB, Stein S, Laskin DL, Sinko PJ. Enhanced passive pulmonary targeting and retention of PEGylated rigid microparticles in rats. Int J Pharm. 2010;402(1–2):64–71.
  23. Kutscher HL, Chao P, Deshmukh M, Singh Y, Hu P, Joseph LB, Reimer DC, Stein S, Laskin DL, Sinko PJ. Threshold size for optimal passive pulmonary targeting and retention of rigid microparticles in rats. J Control Release. 2010;143(1):31–7.
  24. Anumolu SS, Singh Y, Gao D, Stein S, Sinko PJ. Design and evaluation of novel fast forming pilocarpine-loaded ocular hydrogels for sustained pharmacological response. J Control Release. 2009;137(2):152–9.
  25. Anumolu SS, Menjoge AR, Deshmukh M, Gerecke D, Stein S, Laskin J, Sinko PJ. Doxycycline hydrogels with reversible disulfide crosslinks for dermal wound healing of mustard injuries. Biomaterials. 2011;32(4):1204–17.
  26. Anumolu SS, DeSantis AS, Menjoge AR, Hahn RA, Beloni JA, Gordon MK, Sinko PJ. Doxycycline loaded poly(ethylene glycol) hydrogels for healing vesicant-induced ocular wounds. Biomaterials. 2010;31(5):964–74.
  27. Gordon MK, Desantis A, Deshmukh M, Lacey CJ, Hahn RA, Beloni J, Anumolu SS, Schlager JJ, Gallo MA, Gerecke DR, Heindel ND, Svoboda KK, Babin MC, Sinko PJ. Doxycycline hydrogels as a potential therapy for ocular vesicant injury. J Ocul Pharmacol Ther. 2010;26(5):407–19.
  28. Deshmukh M, Singh Y, Gunaseelan S, Gao D, Stein S, Sinko PJ. Biodegradable poly(ethylene glycol) hydrogels based on a self-elimination degradation mechanism. Biomaterials. 2010;31(26):6675–84.
  29. Zhang Y, Huo M, Zhou J, Xie S. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput Methods Programs Biomed. 2010;99(3):306–14.
  30. Haugland RP. Fluorophores and their amine-reactive derivatives. In: Handbook of fluorescent probes and research products. 9 edn. Molecular Probes, Eugene, OR: 2002; pp. 7–78.
  31. Singh Y, Spinelli N, Defrancq E. Chemical strategies for oligonucleotide-conjugate synthesis. Curr Org Chem. 2008;12:263–90.
  32. Kusterle M, Jevsevar S, Porekar VG. Size of pegylated protein conjugates studied by various methods. Acta Chim Slov. 2008;55(3):594–601.
  33. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214–21.
  34. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005;10(21):1451–8.
  35. Joralemon MJ, McRae S, Emrick T. PEGylated polymers for medicine: from conjugation to self-assembled systems. Chem Commun. 2010;46(9):1377–93.
  36. Abuchowski A, van Es T, Palczuk NC, Davis FF. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem. 1977;252(11):3578–81.
  37. Abuchowski A, McCoy JR, Palczuk NC, van Es T, Davis FF. Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase. J Biol Chem. 1977;252(11):3582–6.
  38. Levy Y, Hershfield MS, Fernandez-Mejia C, Polmar SH, Scudiery D, Berger M, Sorensen RU. Adenosine deaminase deficiency with late onset of recurrent infections: response to treatment with polyethylene glycol-modified adenosine deaminase. J Pediatr. 1988;113(2):312–7.
  39. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev. 2003;55(10):1293–302.
  40. Rajender Reddy K, Modi MW, Pedder S. Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C. Adv Drug Deliv Rev. 2002;54(4):571–86.
  41. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002;54(4):547–70.
  42. Sundy JS, Becker MA, Baraf HS, Barkhuizen A, Moreland LW, Huang W, Waltrip 2nd RW, Maroli AN, Horowitz Z. Reduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized study. Arthritis Rheum. 2008;58(9):2882–91.
  43. Manjula BN, Tsai A, Upadhya R, Perumalsamy K, Smith PK, Malavalli A, Vandegriff K, Winslow RM, Intaglietta M, Prabhakaran M, Friedman JM, Acharya AS. Site-specific PEGylation of hemoglobin at Cys-93(beta): correlation between the colligative properties of the PEGylated protein and the length of the conjugated PEG chain. Bioconjug Chem. 2003;14(2):464–72.
  44. Kaminskas LM, Boyd BJ, Karellas P, Krippner GY, Lessene R, Kelly B, Porter CJ. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers. Mol Pharm. 2008;5(3):449–63.
  45. Nair LS, Laurencin CT. Polymers as biomaterials for tissue engineering and controlled drug delivery. In: Lee K, Kaplan D, editors. Advances in biochemical engineering/biotechnology, vol. 102. Berlin-Heidelberg: Springer-Verlag; 2006. p. 47–90.
• 作者单位：1. Department of Pharmaceutics Ernest Mario School of Pharmacy, Rutgers The State University of New Jersey, 160 Frelinghuysen Road, Piscataway, New Jersey 08854, USA2. Dr. Susan Love Research Foundation, 2811 Wilshire Blvd., Suite 500, Santa Monica, California 90403, USA
• ISSN：1573-904X

文摘

Purpose To investigate the influence of nanocarrier molecular size and shape on breast duct retention in normal rats using a non-invasive optical imaging method.